On 9 November, General Secretary and President To Lam attended a ceremony that marked the completion of an exclusive technology transfer between Tam Anh General Hospital System and Japan’s Grandsoul Group. The agreement gives Vietnamese clinicians the right to use Japan’s most advanced stem-cell and immune-cell platforms for oncology, a capability that until now required patients to travel abroad.
The partnership goes far beyond delivering equipment. It includes the hand-over of core processes, a full suite of quality-management protocols, and an intensive training programme for Vietnamese specialists. Japanese experts inspected Tam Anh’s facilities, staff qualifications and laboratory standards before green-lighting the hand-over, ensuring that the new procedures meet the stringent safety criteria typical of Japanese regenerative-medicine centres.
What the transferred technologies entail
The first bundle centres on the isolation, expansion and selective differentiation of mesenchymal stem cells (MSCs) harvested from a patient’s own adipose tissue. After a minimally invasive liposuction, the fat is processed in a clean-room environment, where MSCs are extracted, cultured, and prepared for clinical use. These cells are prized for their ability to modulate immune responses and promote tissue repair, a trait currently explored for cardiovascular disease, neuro-degeneration, metabolic disorders and chronic lung conditions.
The second bundle focuses on natural killer (NK) immune cells. Blood drawn from the patient provides a source of NK cells that are then purified, expanded and activated under specialised conditions. Once re-infused, they are expected to seek out and destroy malignant cells, complementing surgery, chemotherapy or radiotherapy. Professor Matsuo Yoshinobu of the Grandsoul Nara Institute highlighted that both MSC and NK platforms must satisfy strict benchmarks for purity, viability, functional activity and sterility before any clinical application.
Implications for Vietnam’s health system and future cooperation
Tam Anh’s Chairman, Professor Ta Thanh Van, emphasised that the transfer unlocks a new research corridor for Vietnamese scientists. The hospital already operates a Ministry-approved Tissue and Cord Blood Bank and a dedicated Centre for Regenerative Medicine, providing a solid foundation for scaling the new procedures. Dr Pham Xuan Dung, director of the oncology unit, sees NK-cell immunotherapy as a promising adjunct to existing multimodal cancer strategies, while stressing that each cell-therapy must be validated against clinical data and national regulations.
From an economic standpoint, Chairman Ngo Chi Dung described the move as a cornerstone of the hospital system’s high-tech investment roadmap. The ability to offer cutting-edge cell therapies domestically is expected to attract medical tourists, generate new revenue streams, and stimulate joint research projects between Vietnamese and Japanese institutions. This health-sector milestone mirrors a broader shift in Japan-Vietnam relations, where recent bilateral trips have highlighted joint work in semiconductors, artificial intelligence and quantum technologies, signalling a transition from pure technology import to collaborative co-creation.
Building a sustainable regenerative-medicine ecosystem
To ensure long-term success, both sides have agreed on a phased approach: initial clinical pilots, followed by data-driven optimisation, and finally wider roll-out across Vietnam’s public and private hospitals. Continuous knowledge exchange, joint publications and shared intellectual-property frameworks are slated to keep the partnership dynamic. As the domestic expertise deepens, Vietnam could move from a technology-receiver to a co-developer, potentially contributing its own innovations—such as graphene-oxide-based delivery systems—to future generations of cell-based therapies.
The November 9 ceremony not only delivered concrete stem-cell and NK-cell capabilities but also underscored Vietnam’s ambition to become a regional hub for high-tech health services. With regulatory pathways being clarified and infrastructure already in place, the nation stands poised to offer world-class regenerative treatments at home while further cementing its strategic partnership with Japan across a spectrum of emerging technologies.
